TY - JOUR
T1 - Current and future trends in the use of immunosuppressive agents in patients with uveitis
AU - Becker, Matthias D.
AU - Rosenbaum, James T.
PY - 2000
Y1 - 2000
N2 - Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.
AB - Therapeutic trials for uveitis are seldom performed because of the relative rarity of the disease and its heterogeneity. Promising new approaches to therapy include cytokine or cytokine receptor inhibition; cytokine addition (α-interferon or interleukin-10); novel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted corticosteroid implants; and oral tolerance. Additional modalities or targets that deserve further testing include T-cell subsets, adhesion molecules, accessory molecules in antigen presentation, novel inflammatory mediators, inducers of apoptosis, photodynamic therapy, and neuroprotective agents. (C) 2000 Lippincott Williams and Wilkins, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0033668811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033668811&partnerID=8YFLogxK
U2 - 10.1097/00055735-200012000-00015
DO - 10.1097/00055735-200012000-00015
M3 - Article
C2 - 11141644
AN - SCOPUS:0033668811
SN - 1040-8738
VL - 11
SP - 472
EP - 477
JO - Current opinion in ophthalmology
JF - Current opinion in ophthalmology
IS - 6
ER -